Skip to main content
SpringerLink
Log in

Survival of L1210 leukemia cells and normal hematopoietic stem cells following in vivo administration of cyclocytidine

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The survival of L1210 cells following increasing doses of cyclocytidine (cyclo-C) was determined by spleen colony assay. For single dose, cyclo-C was effective reaching a fractional survival of less than 10−3 at 10 mg/mouse. This is significantly more effective than a similar dose of arabinosyl cytosine (ara-C) given by rapid infusion. The time-survival curve demonstrated extended cytotoxicity following a single 10 mg/mouse dose of cyclo-C as expected for a long-acting agent. When a 24-hour infusion was examined, however, ara-C was more effective than cyclo-C by a factor of about 10. The clinical implication of this is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ho DHW, Frei III E: Clinical pharmacology of 1-β-D-ara-binofuranosylcytosine. Clin Pharm Ther 12:944–954, 1971

    Google Scholar 

  2. Creasy WA, Papac RJ, Markiw ME, Calabresi P, Welch AD: Biochemical and pharmacological studies with 1-β-D-arabinofuranosylcytosine in man. Biochem Pharmacol 15:1417–1428, 1966

    Google Scholar 

  3. Edelstein M, Valeriote F, Vietti T: Cellular quantitation of the in vivo effects of 1-β-D-arabinofuranosylcytosine on leukemia L1210. J Natl Cancer Inst 58:941–947, 1977

    Google Scholar 

  4. Skipper HE, Schabel JR FM, Wilcox WS: Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother Rep 51:125–165, 1967

    Google Scholar 

  5. Hoshi A, Iigo M, Saneyoshi M, Kuretani K: Resistance of cyclocytidine to cytidine deaminase. Chem Phar Bull 21:1535–1538, 1973

    Google Scholar 

  6. Pizer LI, Cohen SS: Metabolism of pyrimidine arabino-nucleosides and cyclonucleotides in escherichia coli. J Biol Chem 235:2387–2392, 1960

    Google Scholar 

  7. Hoshi A, Hoshida M, Kuretani K, Kanai T, Ichino M: Metabolism of cyclocytidine and aracytidine in mice. Chem Pharm Bull 23:1814–1818, 1975

    Google Scholar 

  8. Nakamura T, Wakisaka G: Mechanism of action of cyclocytidine in leukemic cells. Bibl Haematol 40:755–756, 1975

    Google Scholar 

  9. Wang MC, Sharma RA, Bloch A: Studies on the mode of action of 2,2′-anhydro-1-β-D-arabinofuranosylcytosine. Cancer Res 33:1265–1271, 1973

    Google Scholar 

  10. Hoshi A, Iigo M, Kuretani K, Kanai T, Ichino M: Auto-radiographic study on the distribution of cyclocytidine in mice. Chem Pharm Bull 22:2311–2317, 1974

    Google Scholar 

  11. Liss RH, Neil GL: Comparative studies of cyclocytidine (NSC-145668) and cytosine arabinoside (NSC-63878). Cancer Chemother Rep 50:501–513, 1975

    Google Scholar 

  12. Hoshi A, Iigo M, Kuretani K, Kanai T, Ichino M: Distribution of cyclocytidine in tissues. Chem Pharm Bull 23:725–728, 1975

    Google Scholar 

  13. Neil GL, Kuentzel SL, Berger AE: A microbiological assay for cyclocytidine-disposition studies in mice. Res Comm Chem Pathol Pharmacol 5:561–572, 1973

    Google Scholar 

  14. Ho DHW: Metabolic fate of 02, 2′-cyclocytidine. Drug Metabol Dispos 1:752–755, 1973

    Google Scholar 

  15. Hoshi A, Kanzawa F, Iigo M, Kuretani K: Effect and toxicity of combination treatment including cyclocytidine or cytosine arabinoside in L1210 and sarcoma-180 systems. Gann 66:539–546, 1975

    Google Scholar 

  16. Nakahara W, Tokuzen R: Effect of 2,2′-0-cyclocytidine on transplanted lymphocytic sarcoma and reticulum cell sarcoma in mice. Gann 63:379–381, 1972

    Google Scholar 

  17. Tokuzen R, Kuretani K, Nakahara W: Effect of cyclo-cytidine on spontaneous mammary adenocarcinoma of mice. Gann 65:89–91, 1974

    Google Scholar 

  18. Venditti JM, Baratta MC, Greenberg NH, Abbott BJ, Kline I: Studies of the L1210 antileukemic activity of 0–2,2′-cyclocytidine monoacetate (anthydro-ara-C; NSC-129220) — Comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency. Cancer Chemother Rep 56:483–492, 1972

    Google Scholar 

  19. Hoshi A, Kanzawa F, Kuretani K: Antitumor activity of Cyclocytidine in a variety of tumors. Gann 63:353–369, 1972

    Google Scholar 

  20. Hoshi A, Kanzawa F, Kuretani K, Saneyoshi M, Arai Y: 2,2′ -0-cyclocytidine, an antitumor cytidine analog resistant to cytidine deaminase. Gann 61:145–146, 1971

    Google Scholar 

  21. Yamada K, Kimura K: Cyclocytidine study in the treatment of acute leukemia. Bibl Haematol 40:753–754, 1975

    Google Scholar 

  22. Hirayma H, Sugihara K, Wakigawa K, Iwamura M, Hikita J, Ohkuma H: Acute toxicity of cyclocytidine, a new antitumor agent, in mouse and rat. Pharmacometrics 6:1255–1258, 1972

    Google Scholar 

  23. Hirayma H, Sugihara K: Wakigawa K, Iwamura M, Hikita J, Ohkuma H: Acute toxicity of cyclocytidine, a new antitumor agent, in mouse and rat. Pharmacometrics 6:1255–1258, 1972

    Google Scholar 

  24. Lokich JJ: Chawla PL, Jaffe N, Frei III E: Phase I evaluation of cyclocytidine (NSC-145668). Cancer Chemother Rep 59:389–393, 1975

    Google Scholar 

  25. Burks TF, Loo TL, Grubb MN: Mechanism of the cardiovascular actions of cyclocytidine. Proc Soc Exp Biol Med 159:374–379, 1978

    Google Scholar 

  26. Valeriote F, Vietti T, Tolen S: Kinetics of the lethal effect of actinomycin D on normal and leukemic cells. Cancer Res 33:2658–2661, 1973

    Google Scholar 

  27. Valeriote F: Cellular aspects of the action of cytosine arabinoside. Med Ped Onc Supp 1:5–26, 1982

    Google Scholar 

  28. Hoshi A, Kanzawa F, Kuretani K: Influence of route of administration on antileukemic activity of cyclocytidine. Gann 63:279–280, 1972

    Google Scholar 

  29. Bruce WR, Meeker BE, Valeriote FA: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233–245, 1966

    Google Scholar 

  30. The Pharmacology of Cytosar-UR as it relates to its therapeutic use. (HD Priesler and GL Royer, eds) Medical and Pediatric Oncology, Supplement 1, Alan R. Liss, Inc. New York, 1981

    Google Scholar 

  31. Gish DT, Neil GL, Wechter WJ: Nucleic acids 12. Synthesis of L enantiomer of 1-β-arabinofuranosylcytosine of 02, 02-anhydro-1-β-D-arabinofuranosylcytosine. J Med Chem 14:882–883, 1971

    Google Scholar 

  32. Miale T, Hvizdala E, Ragab A, Pullen J, O'Brien P, McMillan C: Cyclocytidine in the treatment of refractory acute childhood leukemia: A southwest oncology group phase I–II study. Cancer Treat Rep 63:1913–1915, 1979

    Google Scholar 

  33. Finklestein JZ, Higgins G, Krivit W, Hammond D: Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors. Cancer Treat Rep 63:1331–1333, 1979

    Google Scholar 

  34. O'Bryan RM, Baker L, Whitecar J, Salmon S, Vaughn C, Hoogstraten B: Cyclocytidine in breast cancer. Cancer Treat Rep 62:455–456, 1978

    Google Scholar 

  35. McKelvey EM, Hewlett JS, Thigpen T, Whitecar J: Cyclocytidine chemotherapy for malignant melanoma. Cancer Treat Rep 62:469–471, 1978

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Medicine, Wayne State University, USA

    Fred Valeriote

  2. Department of Experimental Therapeutics, Michigan Cancer Foundation, 48201, Detroit, MI, USA

    Fred Valeriote

  3. Division of Hematology and Oncology, Mallinckrodt Department of Pediatrics, Washington University School of Medicine, 63110, St. Louis, MO, USA

    Ingomar D. Muntz & Teresa J. Vietti

Authors
  1. Fred Valeriote
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ingomar D. Muntz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teresa J. Vietti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valeriote, F., Muntz, I.D. & Vietti, T.J. Survival of L1210 leukemia cells and normal hematopoietic stem cells following in vivo administration of cyclocytidine. Invest New Drugs 3, 255–261 (1985). https://doi.org/10.1007/BF00179429

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00179429

Key words

Search

Navigation